Sanofi India Limited — Investor Meet, 05-03-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sanofi India closed FY25 with 1% PBT and 4% PAT growth, driven by -17% opex efficiency, despite flat domestic sales. Q4 PBT saw a dip. The diabetes business shined, growing 11% in Q4, led by Lantus and Toujeo. Partnership sales were flat yearly but dropped 13% in Q4 due to stock adjustments; volatility is expected in 2026 before stabilizing. Exports declined as anticipated due to a prior divestment. Management is focused on maximizing diabetes opportunities, especially with Soliqua, aiming for sustainable growth post-transformation.